Product Description
Mechanisms of Action: CYP3A4 Inhibitor,P-gp Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Pneumonia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2080224917 | P3 |
Completed |
Pneumonia |
2023-09-30 |